Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | |||||||||||||
| PMID | |||||||||||||
| Authors | Shugaku Takeda, Celia Andreu-Agullo, Subhasree Sridhar, Nils Halberg, Ivo C. Lorenz, Sohail Tavazoie, Isabel Kurth, Masoud Tavazoie | ||||||||||||
| Title | Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor | ||||||||||||
|
|||||||||||||
| URL | https://www.abstractsonline.com/pp8/#!/6812/presentation/9185 | ||||||||||||
| Abstract Text | AACR Annual Meeting 2019, Abstract LB-277 | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RGX-019 | RGX019|RGX 019 | MERTK Antibody 1 | RGX-019 is a monoclonal antibody that selectively targets Mertk for internalization and degradation, leading to inhibition of cancer cell growth (AACR Annual Meeting 2019, Abstract LB-277). |
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|